NCT05735028View on ClinicalTrials.gov

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 7, 2024

Primary Completion Date

August 7, 2025

Study Completion Date

December 7, 2025

Conditions
Lung Cancer
Interventions
DRUG

Centipeda minima+PD-1/PD-L1 inhibitor

Before routine anti-PD-1/PD-L1 treatment, patients were treated with Centipeda minima, and15g Centipeda minima decoction was taken twice a day for 5 consecutive days.

DRUG

PD-1/PD-L1 inhibitor

PD-1/PD-L1 inhibitor

Trial Locations (1)

Unknown

RECRUITING

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER